Efficacy and Safety of Actinium-225 Prostate-Specific Membrane Antigen Radioligand Therapy in Metastatic Prostate Cancer: A Systematic Review and Metanalysis
Medical Principles and Practice · 2023
DOI: 10.1159/000531246 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Medical Principles and Practice, 2023. Verfasst von Girish Kumar Parida und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, All India Institute of Medical Sciences, Bhubaneswar, India. Hauptthemen laut MEDLINE: Actinium, Prostatic Neoplasms, Castration-Resistant. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Actinium-225 (Ac-225) labelled PSMA RLT has been tested recently in metastatic castration-resistant prostate cancer (mCRPC), with encouraging results. Ac-225, being an alpha emitter, is expected to have higher efficacy and fewer side effects compared to the beta-emitters such as Lutetium-177. We have performed a meta-analysis to assess the therapeutic responses, survival effects, and significant side effects of Ac-225 PSMA RLT in patients with mCRPC. Methodology: Systematic literature search was carried out from five electronic databases PubMed/MEDLINE, SCOPUS, EMBASE, Web of Science, and Cochrane Library until March 2021. Eight studies were found to be eligible for this metanalysis.
Results
Eight studies with 226 patients were analyzed in this metanalysis. 81% (95% CI 73–89) patients had a decline in PSA levels. 60% of the patients showed more than 50% PSA decline. Two studies assessed survival effects of radioligand naïve patients compared to patients who had received Lu-PSMA therapy previously and the pooled HR for radioligand naïve patients is 0.22. The most common toxicity reported was xerostomia in 167 patients out of 226 patients (73.9%, 95% CI 67.6–79.5%); however, most of them were confined to grade I and II levels. Other reported side effects include hematologic toxicity and nephrotoxicity.
Conclusion
Ac-PSMA RLT is a safe and potentially effective treatment option for patients with mCRPC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, All India Institute of Medical Sciences, Bhubaneswar, India.
Zitieren
APA
Parida, G. K., Panda, R. A., Bishnoi, K., & Agrawal, K. (2023). Efficacy and Safety of Actinium-225 Prostate-Specific Membrane Antigen Radioligand Therapy in Metastatic Prostate Cancer: A Systematic Review and Metanalysis. Medical Principles and Practice. https://doi.org/10.1159/000531246
Vancouver
Parida GK, Panda RA, Bishnoi K, Agrawal K. Efficacy and Safety of Actinium-225 Prostate-Specific Membrane Antigen Radioligand Therapy in Metastatic Prostate Cancer: A Systematic Review and Metanalysis. Medical Principles and Practice. 2023. doi:10.1159/000531246
BibTeX
@article{Parida2023,
author = {Parida, Girish Kumar and Panda, Raj Abhisek and Bishnoi, Komal and Agrawal, Kanhaiyalal},
title = {Efficacy and Safety of Actinium-225 Prostate-Specific Membrane Antigen Radioligand Therapy in Metastatic Prostate Cancer: A Systematic Review and Metanalysis},
journal = {Medical Principles and Practice},
year = {2023},
doi = {10.1159/000531246}
}
EUVIMED